Nicole describes her work at Metrion, the technologies she used and how they complemented her PhD research.

As we approach the close of our 10th anniversary year, we reflect on how far Metrion has come, from its scientific roots to becoming a trusted partner in ion channel drug discovery.

Our campaign launched high-throughput NaV1.9 assays which enable our customers to accelerate discovery of novel, non-opioid pain therapeutics with greater efficiency and confidence.

This nomination recognises the outstanding performance of Metrion’s commercial team during the company’s 10th anniversary year, a period that also presented significant challenges across the global life sciences industry.

Cost-effective expertise during critical phases of research, without sacrificing quality

Beth Sharp, Biomedical Sciences student at the University of Manchester, reviews her industrial placement year at Metrion

'Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics) receives ‘2024 Technology Innovation Publication Award’.

Students learned about electrophysiology concepts, sodium channels in drug discovery and the commercial business-side of ion channels

Review of CICF, bringing together a dynamic community of experts in ion channel research

In light of the FDA’s changing stance, the Volta assay emerges as a powerful, validated NAM capable of addressing the very safety concerns traditionally assessed in animal studies.